Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


1 Ann Surg Oncol
1 Anticancer Res
1 Arch Pathol Lab Med
1 BMC Cancer
1 Br J Dermatol
1 Cancer
1 Clin Cancer Res
1 J Invest Dermatol
1 J Surg Oncol
1 Lancet Oncol
2 Melanoma Res
1 Nat Med

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Surg Oncol

  1. NESSIM C, Crawford AB
    ASO Author Reflections: Wait Times for Melanoma Surgery.
    Ann Surg Oncol. 2018 Dec 4. pii: 10.1245/s10434-018-7022.
    PubMed     Text format    

    Anticancer Res

  2. TROJAN SE, Piwowar M, Ostrowska B, Laidler P, et al
    Analysis of Malignant Melanoma Cell Lines Exposed to Hypoxia Reveals the Importance of PFKFB4 Overexpression for Disease Progression.
    Anticancer Res. 2018;38:6745-6752.
    PubMed     Text format     Abstract available

    Arch Pathol Lab Med

  3. WILLIAMS MD, Franchi A, Helliwell T, Muller S, et al
    Data Set for Reporting of Mucosal Melanomas of the Head and Neck: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting.
    Arch Pathol Lab Med. 2018 Nov 30. doi: 10.5858/arpa.2018-0412.
    PubMed     Text format     Abstract available

    BMC Cancer

  4. SEGAOULA Z, Primot A, Lepretre F, Hedan B, et al
    Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology.
    BMC Cancer. 2018;18:1219.
    PubMed     Text format     Abstract available

    Br J Dermatol

  5. FOX JA, Langbecker D, Rosenberg J, Ekberg S, et al
    Uncertain diagnosis and prognosis in advanced melanoma: A qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies.
    Br J Dermatol. 2018 Dec 4. doi: 10.1111/bjd.17511.
    PubMed     Text format     Abstract available


  6. SAAB KR, Mooradian MJ, Wang DY, Chon J, et al
    Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31889.
    PubMed     Text format     Abstract available

    Clin Cancer Res

  7. JOSEPH RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, et al
    Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
    Clin Cancer Res. 2018;24:6098.
    PubMed     Text format    

    J Invest Dermatol

  8. FERRIS L, Moy R, Gerami P, Sligh JE, et al
    Non-Invasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma.
    J Invest Dermatol. 2018 Nov 27. pii: S0022-202X(18)32894.
    PubMed     Text format     Abstract available

    J Surg Oncol

  9. KANG R, Columbo JA, Trooboff SW, Servos MM, et al
    Receipt of sentinel lymph node biopsy for thin melanoma is associated with distance traveled for care.
    J Surg Oncol. 2018 Dec 3. doi: 10.1002/jso.25314.
    PubMed     Text format     Abstract available

    Lancet Oncol

  10. GROB JJ, Garbe C, Ascierto P, Larkin J, et al
    Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?
    Lancet Oncol. 2018;19:e720-e725.
    PubMed     Text format     Abstract available

    Melanoma Res

  11. BLOCK MS, Nevala WK, Pang YP, Allred JB, et al
    A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
    Melanoma Res. 2018 Dec 4. doi: 10.1097/CMR.0000000000000556.
    PubMed     Text format     Abstract available

  12. CIMMINIELLO C, Indini A, Di Guardo L, Prisciandaro M, et al
    Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
    Melanoma Res. 2018 Dec 4. doi: 10.1097/CMR.0000000000000539.
    PubMed     Text format     Abstract available

    Nat Med

  13. TRUCCO LD, Mundra PA, Hogan K, Garcia-Martinez P, et al
    Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
    Nat Med. 2018 Dec 3. pii: 10.1038/s41591-018-0265.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.